Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion. Net income attributable to Biogen Inc. was $266.8 million, or $1.83 per share, compared to $249.7 million, or $1.71 per share, last year. Adjusted EPS grew 17% YoY to $3.44. For full-year 2025, […]
“Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion. Net income attributable to Biogen Inc. was $266.8 million, or $1.83 per share, compared to $249.7 million, or $1.71 per share, last year. Adjusted EPS grew 17% YoY to $3.44. For full-year 2025, […]
· February 12, 2025
Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today.
Total revenue increased 3% year-over-year to $2.5 billion.
Net income attributable to Biogen Inc. was $266.8 million, or $1.83 per share, compared to $249.7 million, or $1.71 per share, last year. Adjusted EPS grew 17% YoY to $3.44.
For full-year 2025, the company expects total revenue to decline by a mid-single digit percentage at constant currency versus full-year 2024. Adjusted EPS is expected to be $15.25-16.25.
